BofA raised the firm’s price target on Boston Scientific (BSX) to $100 from $90 and keeps a Buy rating on the shares. The firm, which sees Boston Scientific having “best in medtech growth ...
Boston Scientific Corporation’s stock is up 53.1% in 2024, up 4.4% in the previous five trading days and up 72.04% in the past year. Currently, Boston Scientific Corporation’s price-earnings ratio is ...
TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once ...
Needham has recently reduced Boston Scientific Corporation (BSX) stock to Hold rating, as announced on October 18, 2024, according to Finviz. Earlier, on May 30, 2024, Goldman had initiated the stock ...
Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenue/EPS ahead of ...
Boston Scientific Corporation’s stock is up 52.7% in 2024, up 5.5% in the previous five trading days and up 69.35% in the past year. Currently, Boston Scientific Corporation’s price-earnings ratio is ...
Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...